CN1210039C - Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use - Google Patents
Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use Download PDFInfo
- Publication number
- CN1210039C CN1210039C CN 02128126 CN02128126A CN1210039C CN 1210039 C CN1210039 C CN 1210039C CN 02128126 CN02128126 CN 02128126 CN 02128126 A CN02128126 A CN 02128126A CN 1210039 C CN1210039 C CN 1210039C
- Authority
- CN
- China
- Prior art keywords
- ferulic acid
- cardiovascular
- diabetes
- radix notoginseng
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a composition used for preventing and treating cardiovascular and cerebrovascular diseases and diabetes and application thereof. Although panax notoginseng saponins and ferulic acid have certain therapeutic effect on cardiovascular and cerebrovascular diseases and concurrent diseases of diabetes, the comprehensive therapeutic effect of the panax notoginseng saponins and the ferulic acid needs to be enhanced. Although some compound preparations (such as compound red sage roots, etc.) used for preventing and treating cardiovascular and cerebrovascular diseases and diabetes exist in traditional medicine, ingredients of the compound preparations are complicated, the relationship among formulations is not clear, the prescription is not precise, and the quality is not easily controlled. The composition which is a product of the present invention is prepared from the following raw material according to the weight percentage: 5 wt% to 95 wt% of panax notoginseng saponin and 5 wt% to 95 wt% of ferulic acid. The panax notoginseng saponins and the ferulic acid are matched to form mutual cooperation, functions of blood are regulated by the panax notoginseng saponins and the ferulic acid, and diseases caused by variation of the blood system, or the cardiovascular system, or the cerebral vessel, or blood sugar, or functional disorder is treated or improved. The product has the purpose that a right quantity of medical or edible auxiliary material is matched so that a preparation which can be accepted by medicine or food is prepared. The present invention has the advantages of good comprehensive therapeutic effect, precise prescription and easy control of quality.
Description
Technical field:
The present invention relates to a kind of compositions that is used to prevent and treat cardiovascular and cerebrovascular disease and diabetic complication, particularly relate to the compositions of the biologically active of a kind of Radix Notoginseng total arasaponins and ferulic acid composition, and the purposes of said composition on preparation medicine and food.
Background technology
Radix Notoginseng (having another name called Radix Notoginseng, Radix Notoginseng, southern Radix Ginseng) is the araliaceae ginseng plant, and its root, leaf, flower etc. all have medical value, mainly contain ginsenoside and other material.Research data confirms that the Radix Notoginseng total arasaponins that extracts in the Radix Notoginseng has the sanguimotor hemodynamics of the improvement of effect, blood viscosity lowering, and effects such as blood fat reducing, beauty treatment are the natural extracts of using always, and national standard is arranged.Ferulic acid is one of Radix Angelicae Sinensis, Rhizoma Chuanxiong main component.Functions such as ferulic acid has antioxidation, anticoagulant and antithrombotic formation, blood fat reducing, resists myocardial ischemia, microcirculation improvement, beauty treatment.Though Radix Notoginseng total arasaponins and ferulic acid have certain curative effect to cardiovascular and cerebrovascular disease and diabetic complication, its comprehensive therapeutic effect has much room for improvement.Though traditional medicine has some compound recipes that are used to prevent and treat cardiovascular and cerebrovascular disease and diabetes (as compound Salviae Miltiorrhizae etc.), not concise, the difficult control of quality of ambiguity, prescription between its complicated component, the prescription.
Summary of the invention
Purpose of the present invention aims to provide a kind of Radix Notoginseng total arasaponins and ferulic acid composition product that is used to prevent and treat cardiovascular and cerebrovascular disease and diabetic complication, require that its comprehensive therapeutic effect is good, prescription is concise, system easy to control the quality, and the purposes of this product on preparation medicine and food is provided.
Product of the present invention is made up of following raw materials by weight percent:
Radix Notoginseng total arasaponins (PNS): 5%～95%
Ferulic acid (ferulic acid FA): 5%～95%
And be equipped with an amount of medicinal or edible adjuvant, make acceptable preparation on medicine or the food.
The formula optimization weight percentage ranges of product of the present invention is:
Radix Notoginseng total arasaponins (PNS): 20%～80%
Ferulic acid (femlic acid FA): 80%～20%
Raw material Radix Notoginseng total arasaponins in the product of the present invention and ferulic acid etc. all have available commercial.
Pharmaceutical adjuvant of the present invention is mannitol, sorbitol, lactose, sucrose, starch and derivant thereof, cellulose and derivant thereof, aminoacid and derivant thereof, NaCl, CaCl
2, CaCO
3Deng the organic or inorganic thing.The adjuvant that food is used is soybean oil, Oleum Arachidis hypogaeae semen, Polyethylene Glycol-400 (PEG-400), flour, osseocolla, pectin, gelatin, xanthan gum, Folium Camelliae sinensis, Mel etc.
Can be made into medical treatment with product of the present invention and go up acceptable multiple drug form and functional food, as: the tablet of injectable powder, drop, oral agents, glue are assisted agent, granule and cookies, confection, beverage, fruit jelly etc.
Blood is the metabolic carrier of the new one-tenth of human body, and it has transportation, keeps the relatively stable of interior environment, and the function of defence.Blood goes wrong, and will directly influence the performance of its function.Blood constantly circulates in the blood vessel of whole body, and blood and blood vessel influence each other.Therefore, the disease of cardiovascular system, light then influence people's new one-tenth metabolism, accelerate human senility; Heavy then critical illness such as myocardial infarction, apoplexy take place.The scientific research of this product process finds that Radix Notoginseng total arasaponins can improve hemodynamics, improves blood quality, prevent the generation of hemostatic tube and neural inflammation that ferulic acid then has activating blood circulation to dissipate blood stasis, removes effects such as the interior free radical of blood vessel, inhibition platelet activating factor.Both can work in coordination with mutually at 5 usefulness, regulate blood function, treatment jointly or improve disease or the functional disorder that causes because of blood system or cardiovascular and cerebrovascular vessel variation or change of blood sugar.
The pharmacological experiments of this product is as follows:
1. this product is to the influence of rat fat
Method: high fat emulsifying agent preparation: with cholesterol, propylthiouracil sheet pulverize.Be mixed with lipomul (W/V) by 10% cholesterol, 2% cholate, 1% propylthiouracil, 20% Adeps Sus domestica amount with distilled water.Refrigerator is preserved, and the time spent places in the hot bath and melts.
This product is to the influence of rat hyperlipidemia model serum lipids: with 40 of SD rats, be divided at random: (1) normal control group; (2) model control group; (3) this product high dose group of embodiment 1 gained; (4) this product low dose group of embodiment 1 gained.Every group of 10 rats, male and female half and half.Grouping back animal every morning: (1) group is given distilled water (filling stomach), and (2) (3) (4) group is given isopyknic high lipoprotein emulsion (filling stomach).(3) and (4) group is given (filling stomach) this product 145mg/kg, 290mg/kg respectively then, and (1) and (2) group is given (filling stomach) distilled water, continuous 20 days.After the last administration, animal fasting 16 hours, get blood from rat eye socket venous plexus, separation of serum is with enzymatic assays serum cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein, LDL (LDL-C), ApoA (APOA), apolipoprotein B (APOB).
The results are shown in following table.By table as seen, this product high dose group can significantly reduce the TC (P＜0.05) in the hyperlipidemia model rat serum, and low dose group also has reduction trend; Two groups of TG are reduced significantly (P＜0.01).
This product is to the influence of rat hyperlipidemia model blood lipid level (n=10 x ± SD)
Group TC (mmol/L) TG (mmol/L) HDLC (mmol/L) LDL-C (mmol/L)
Normal control group 1.36 ± 1.01 0.93 ± 0.27 0.97 ± 0.25 1.19 ± 0.18
Model control group 2.66 ± 0.34 1.15 ± 0.23 1.13 ± 0.36 1.13 ± 0.17
High dose group 2.32 ± 0.27
*0.51 ± 0.22
*1.08 ± 0.22 0.93 ± 0.28
Low dose group 2.43 ± 0.26 0.53 ± 0.19
*1.02 ± 0.27 1.22 ± 0.22
Model control group and normal control group compare: Δ P＜0.05 Δ Δ P＜0.01
Administration group and model control group compare: * P＜0.05 * * P＜0.01
2. this product influences material and method to diabetes rat blood activities of antioxidant enzymes and mda content
Animal Model Making: male Wistar rat, body weight 180～210g is made into STZ with the aseptic citric acid-sodium citrate buffer of 0.1mol/L 0.45% solution, behind the animal fasting 10h, lumbar injection STZ, 72h, tail vein blood afterwards, the sugar＞16.65mmol/L person that has a blood test is the DM rat.
Grouping and mensuration are as following table
Each organizes rat blood serum SOD, CAT, MDA, GSH-Px level (x ± s)
Group n SOD (NU/ml) CAT (U/ml) MDA (nmol/ml) GSH-Px (u/ml)
Normal group 8 170.02 ± 55.98 26.01 ± 1.73 9.42 ± 2.78 132.09 ± 8.50
DM organizes 8 88.12 ± 20.14 15.96 ± 3.21 91.10 ± 13.59 154.88 ± 6.40
Treatment organizes 8 143.10 ± 36.78 21.98 ± 2.00 34.44 ± 12.03 148.44 ± 11.18
Conclusion
This product can improve the activity of the intravital antioxidase of diabetes rat, reduces the MDA level, thereby can have therapeutical effect to chronic complicating diseases of diabetes.
Good effect of the present invention is that comprehensive therapeutic effect is good, prescription is concise, system easy to control the quality.
The specific embodiment
Embodiment 1: compound notoginsen triterpenes and ferulic acid blood fat reducing granule
Prescription:
Radix Notoginseng total arasaponins 95g
Ferulic acid 5g
Sucrose 3000g
Dextrin 400g
Ethanol is an amount of
Granulate by common granulation, be distributed into 1000 bags (every bag of about 3.5g).Each edible one bag, every day 1～2 time.
Embodiment 2: compound notoginsen triterpenes and ferulic acid soft gelatin capsule
Prescription:
Radix Notoginseng total arasaponins 75g
Ferulic acid 25g
Polyethylene Glycol-400 300g
By common soft gelatin capsule preparation method preparation, the tolerant heavy about 400mg of every intragranular can get 1000.
Treat 35 routine infractions with this product, after treatment in 28 days, the patient more than 95% has obtained alleviation in various degree, and wherein produce effects 44.2%, improves 52.8%.To Electrocardiographic total effective rate is 66.4%.
Embodiment 3: compound notoginsen triterpenes and ferulic acid freeze-dried powder
Prescription:
Radix Notoginseng total arasaponins 125g
Ferulic acid 75g
Mannitol 100g
Be prepared into lyophilized formulations by common lyophilization, can make the compound notoginsen triterpenes and the ferulic acid freeze-dried powder of the specification of 1000 200mg.
Compound notoginsen triterpenes and ferulic acid powder pin pharmacodynamics test
With equal-volume normal saline (N S), FUFANG DANSHEN ZHUSHEYE and compound notoginsen triterpenes and ferulic acid powder pin respectively as negative control group, positive controls and experimental group, the dirty coronary flow minimizing of guinea-pig heart (p＜0.01) is dose-effect relationship due to compound notoginsen triterpenes and the ferulic acid powder pin antagonism pituitrin, is better than the compound Salviae Miltiorrhizae group.On anesthetized rat ligation ramus descendens anterior arteriae coronariae sinistrae myocardial infarction and ischemia model, compound notoginsen triterpenes and ferulic acid powder pin 35,70mg/kg obviously dwindle infarction size than the NS matched group, alleviate the sum of ischemia ST section and raise and reduce serum CPK and the LDH aspect is better than the compound Salviae Miltiorrhizae group.Pallasiomy cerebral ischemia reperfusion damage model, compound notoginsen triterpenes and ferulic acid powder pin 35,70mg/kg and FUFANG DANSHEN ZHUSHEYE 2000mg/kg all show reduction ischemia cerebral edema and calcium content.
Embodiment 4: compound notoginsen triterpenes and ferulic acid oral liquid
Prescription:
Radix Notoginseng total arasaponins 45g
Ferulic acid 155g
Mel 1000g
Distilled water adds to 10kg
By common oral liquor preparation, can get the oral liquid of 1000 (every nearly weighs 11g).
Compound notoginsen triterpenes and ferulic acid oral liquid treatment diabetic complication
To 62 routine diabetics random packet, observe contrast before and after treating.Control experiment between group, the result shows that compound notoginsen triterpenes and ferulic acid oral liquid treatment diabetic complication effect are remarkable, total effective rate reaches 88.4%, compares with the matched group FUFANG DANSHEN JIAONANG, has significant difference.In addition, this product can also reduce serum total cholesterol, triglyceride, reduces blood viscosity, microcirculation improvement.
Above embodiment is only for the present invention is described further, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Claims (8)
1, a kind of Radix Notoginseng total arasaponins and ferulic acid composition that is used to prevent and treat cardiovascular and cerebrovascular disease and diabetic complication is characterized in that being made up of following raw materials by weight percent:
Radix Notoginseng total arasaponins 5%～95%
Ferulic acid 5%～95%
2, as said Radix Notoginseng total arasaponins and the ferulic acid composition that is used to prevent and treat cardiovascular and cerebrovascular disease and diabetic complication of claim 1, it is characterized in that forming by following raw materials by weight percent:
Radix Notoginseng total arasaponins 20%～80%
Ferulic acid 20%～80%
3, as the purposes of the said compositions of claim 1, it is characterized in that being equipped with an amount of medicinal or edible adjuvant, make acceptable preparation on medicine or the food.
4,, it is characterized in that being used to make the oral drugs of control cardiovascular and cerebrovascular disease as the purposes of the said compositions of claim 3.
5,, it is characterized in that said oral drugs are granule, oral liquid, tablet or soft gelatin capsule as the purposes of the said compositions of claim 4.
6,, it is characterized in that being used to make the injectable powder or the drop of control cardiovascular and cerebrovascular disease as the purposes of the said compositions of claim 3.
7,, it is characterized in that being used to make treatment or improve because of the concurrent microcirculation of diabetes and the medicine of Peripheral nerve disease as the purposes of the said compositions of claim 3.
8, as the said purposes that is used to prevent and treat the Radix Notoginseng total arasaponins and the ferulic acid composition of cardiovascular and cerebrovascular disease and diabetic complication of claim 3, it is characterized in that being used to make functional food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02128126 CN1210039C (en) | 2002-12-26 | 2002-12-26 | Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02128126 CN1210039C (en) | 2002-12-26 | 2002-12-26 | Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511534A CN1511534A (en) | 2004-07-14 |
| CN1210039C true CN1210039C (en) | 2005-07-13 |
Family
ID=34231236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02128126 Expired - Fee Related CN1210039C (en) | 2002-12-26 | 2002-12-26 | Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1210039C (en) |
-
2002
- 2002-12-26 CN CN 02128126 patent/CN1210039C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1511534A (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1278737C (en) | Compound medicinal formulation with bioactivity | |
| CN100339111C (en) | Medicine for treating coronary heart disease and its prepn | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN107753535B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and application thereof | |
| CN1209133C (en) | Medicine for preventing and curing rachitis and osteoporosis and method for preparing the same | |
| CN106728679B (en) | Molecular traditional Chinese medicine sustained-release tablet for resisting bone mass loss and preparation method thereof | |
| CN101455739A (en) | Pure traditional Chinese medicine preparation for treating hyperlipemia | |
| CN1173707C (en) | Medicinal composition containing baicalin and caffoeoylchinic acid | |
| CN1923227A (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1210039C (en) | Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use | |
| CN1565420A (en) | Oral nano nourishing emulsion and its preparation method | |
| CN1742919A (en) | Shuerjing Chinese medicine preparation and preparing method thereof | |
| CN1857449A (en) | Chinese medicine for treating puerperal hypogalactia | |
| CN1279944C (en) | Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation | |
| CN115040612A (en) | Composition for regulating hypertension and preparation method thereof | |
| CN1261109C (en) | Compound formulation of adjusting, curing or improving blood function | |
| CN1679593A (en) | Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN1144681A (en) | Strong kidney tonic preparation | |
| CN1201743C (en) | Composition of gensenoside Rg1 and ferulic acid for preventing and treating cardiac and cerebral vascular diseases and diabetes and its application | |
| CN1242801C (en) | Medicinal composition for treating coronary heart disease and angine pectoris | |
| CN115154508A (en) | Preparation method and application of traditional Chinese medicine compound nanoparticles | |
| CN1709455A (en) | Medicinal formulation for treating cervical vertebra, and its preparing method | |
| CN105687567A (en) | Preparation for preventing and treating diarrhea caused by chemotherapy and preparation method of preparation | |
| CN111000249A (en) | Weight-losing and blood sugar-reducing compound plant polypeptide oral liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN WUXIN INDUSTRY CO., LTD. Free format text: FORMER OWNER: KEKAI BIOLOGICAL ENGINEERING CO., LTD., KUNMING Effective date: 20101129 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650224 (KUNMING KEKAI BIOLOGICAL ENGINEERING CO., LTD.), NO.436, BAIYUN ROAD, KUNMING CITY, YUNNAN PROVINCE TO: 651701 WUXIN ROAD, INDUSTRY DEVELOPMENT ZONE, YANGLIN TOWN, SONGMING COUNTY, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101129 Address after: 651701 Yunnan County in Songming Province Yang Lin Zhen Wuxin Industrial Development Zone Road Patentee after: Yunnan Wuxin Industry Co., Ltd. Address before: Baiyun road 650224 Yunnan city of Kunming province (No. 436 Kunming chemwin Biological Engineering Co., Ltd.) Patentee before: Kekai Biological Engineering Co., Ltd., Kunming |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050713 Termination date: 20191226 |